Eisenberger, M.A.

patient cancer response prostate trial prostate cancer survival disease treatment baseline androgen therapy tumor study metastatic androgen deprivation therapy objective deprivation tax 327 trial objective tumor response group result analysis metastase oncol month decline normalization progression alp normalization randomized change androgen deprivation bone metastases objective response lhrh-a increase factor table day 90 chemotherapy bicalutamide prognostic hormone mortality radiation oncology evaluable metastatic crpc phase castration urology score orchiectomy fl utamide outcome level fracture evidence j clin oncol radiation therapy metastatic disease benefit association pain response signi european 10 yr difference objective responses population criteria agonist docetaxel / urologic oncology effect gleason bone metastasis prostate-speci fic antigen retrospective